
Julien Seneschal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7726253/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Human Epidermal Langerhans Cells Maintain Immune Homeostasis in Skin by Activating Skin Resident Regulatory T Cells. Immunity, 2012, 36, 873-884.	14.3	381
2	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2717-2744.	2.4	220
3	OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response. Immunity, 2015, 42, 1159-1170.	14.3	189
4	Platelet CD154 Potentiates Interferon-α Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus. Science Translational Medicine, 2010, 2, 47ra63.	12.4	174
5	Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3. Journal of Investigative Dermatology, 2018, 138, 355-364.	0.7	168
6	Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy. Clinical Reviews in Allergy and Immunology, 2018, 54, 52-67.	6.5	155
7	European Dermatology Forum S1â€guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1401-1424.	2.4	148
8	Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatments. British Journal of Dermatology, 2009, 161, 1081-1088.	1.5	147
9	Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo. Journal of the American Academy of Dermatology, 2017, 76, 863-870.	1.2	128
10	Type <scp>I</scp> interferon signature in the initiation of the immune response in vitiligo. Pigment Cell and Melanoma Research, 2014, 27, 398-407.	3.3	118
11	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARSâ€Covâ€2) infection and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e241-e242.	2.4	99
12	Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: A case–control study. Journal of Hepatology, 2010, 53, 1035-1040.	3.7	92
13	Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. British Journal of Dermatology, 2012, 167, 1138-1144.	1.5	91
14	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1644-1659.	2.4	85
15	The Vitiligo Impact Patient Scale (VIPs): Development and Validation of a Vitiligo Burden Assessment Tool. Journal of Investigative Dermatology, 2016, 136, 52-58.	0.7	83
16	European dermatology forum S1â€guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1581-1594.	2.4	79
17	Loss of epidermal hypoxia-inducible factor- $1\hat{l}\pm$ accelerates epidermal aging and affects re-epithelialization in human and mouse. Journal of Cell Science, 2011, 124, 4172-4183.	2.0	76
18	Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis. British Journal of Dermatology, 2017, 177, 1367-1375.	1.5	75

#	Article	IF	CITATIONS
19	CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice. Immunity, 2016, 45, 209-223.	14.3	73
20	Alopecia areata occurring during anti-TNF therapy: A national multicenter prospective study. Journal of the American Academy of Dermatology, 2014, 70, 1146-1149.	1.2	66
21	An update on Vitiligo pathogenesis. Pigment Cell and Melanoma Research, 2021, 34, 236-243.	3.3	61
22	Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology, 2016, 55, 1664-1672.	1.9	58
23	Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. British Journal of Dermatology, 2013, 168, 756-761.	1.5	57
24	Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab. JAMA Dermatology, 2019, 155, 1312.	4.1	56
25	Pre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo. British Journal of Dermatology, 2012, 167, 490-495.	1.5	55
26	MicroRNA-211 Regulates Oxidative Phosphorylation and Energy Metabolism in Human Vitiligo. Journal of Investigative Dermatology, 2017, 137, 1965-1974.	0.7	55
27	Toxicity profiles of immunotherapy. , 2018, 181, 91-100.		55
28	Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e74-e76.	2.4	53
29	Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the <scp>TOPICOP</scp> score. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1713-1719.	5.7	52
30	GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. British Journal of Dermatology, 2019, 180, 647-656.	1.5	51
31	Living with vitiligo: results from a national survey indicate differences between skin phototypes. British Journal of Dermatology, 2015, 173, 607-609.	1.5	47
32	Eczema Herpeticum: Clinical and Pathophysiological Aspects. Clinical Reviews in Allergy and Immunology, 2020, 59, 1-18.	6.5	47
33	Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients. British Journal of Dermatology, 2011, 165, 44-49.	1.5	46
34	OX40L/OX40 axis impairs follicular and natural Treg function in human SLE. JCI Insight, 2018, 3, .	5.0	46
35	Follicular vitiligo: A report of 8 cases. Journal of the American Academy of Dermatology, 2016, 74, 1178-1184.	1.2	45
36	Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. European Journal of Cancer, 2021, 157, 474-484.	2.8	45

#	Article	IF	CITATIONS
37	Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo. British Journal of Dermatology, 2012, 166, 539-544.	1.5	43
38	Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. British Journal of Dermatology, 2012, 167, 417-423.	1.5	42
39	Platelets Induce Thymic Stromal Lymphopoietin Production by Endothelial Cells: Contribution to Fibrosis in Human Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 2784-2794.	5.6	42
40	Halo Nevi Association in Nonsegmental Vitiligo Affects Age at Onset and Depigmentation Pattern. Archives of Dermatology, 2012, 148, 497.	1.4	41
41	Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata. British Journal of Dermatology, 2018, 179, 534-536.	1.5	40
42	Interest of High-Dose Pulse Corticosteroid Therapy Combined with Methotrexate for Severe Alopecia Areata: A Retrospective Case Series. Dermatology, 2012, 224, 369-373.	2.1	39
43	Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference. Pigment Cell and Melanoma Research, 2017, 30, 28-40.	3.3	38
44	Langerin + Dermal DC, but Not Langerhans Cells, Are Required for Effective CD8-Mediated Immune Responses after Skin Scarification with Vaccinia Virus. Journal of Investigative Dermatology, 2014, 134, 686-694.	0.7	37
45	CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica, 2015, 100, 1086-95.	3.5	37
46	The impact of atopic dermatitis on sexual health. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 428-432.	2.4	36
47	Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis. JCI Insight, 2019, 4, .	5.0	34
48	NKG2D Defines a Subset of Skin Effector Memory CD8 T Cells with Proinflammatory Functions in Vitiligo. Journal of Investigative Dermatology, 2020, 140, 1143-1153.e5.	0.7	32
49	Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A systematic review and meta-analysis. Joint Bone Spine, 2018, 85, 155-163.	1.6	31
50	Sweet syndrome induced by SARS oVâ€2 Pfizerâ€BioNTech mRNA vaccine. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3194-3196.	5.7	31
51	Type-1 cytokines regulate matrix metalloprotease-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight, 2020, 5, .	5.0	31
52	TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2021, 80, 1594-1603.	0.9	30
53	Vitiligo, From Physiopathology to Emerging Treatments: A Review. Dermatology and Therapy, 2020, 10, 1185-1198.	3.0	29
54	Atopic Dermatitis Burden Scale for Adults: Development and Validation of a New Assessment Tool. Acta Dermato-Venereologica, 2015, 95, 700-705.	1.3	27

#	Article	IF	CITATIONS
55	Reproducibility of capillaroscopic classifications of systemic sclerosis: results from the SCLEROCAP study. Rheumatology, 2017, 56, 1713-1720.	1.9	27
56	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVIDâ€19 (SARSâ€CoVâ€2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e308-e311.	2.4	27
57	Development and validation of the <scp>K</scp> â€ <scp>VSCOR</scp> for scoring <scp>K</scp> oebner's phenomenon in <scp>v</scp> itiligo/nonâ€segmental vitiligo. Pigment Cell and Melanoma Research, 2013, 26, 402-407.	3.3	26
58	Importance of outâ€ofâ€pocket costs for adult patients with atopic dermatitis in France. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1921-1927.	2.4	26
59	Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells. Experimental Dermatology, 2019, 28, 656-661.	2.9	26
60	Expression of interleukin-1 alpha in amicrobial pustulosis of the skin folds with complete response to anakinra. Journal of the American Academy of Dermatology, 2014, 71, e53-e56.	1.2	25
61	Risk of severe allergic reactions to COVIDâ€19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e362-e365.	2.4	24
62	Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis. Joint Bone Spine, 2018, 85, 663-668.	1.6	23
63	Vitiligo Skin T Cells Are Prone to Produce Type 1 and Type 2 Cytokines to Induce Melanocyte Dysfunction and Epidermal Inflammatory Response Through Jak Signaling. Journal of Investigative Dermatology, 2022, 142, 1194-1205.e7.	0.7	23
64	Psoriasiform Drug Eruptions Under Anti-TNF Treatment of Arthritis are Not True Psoriasis. Acta Dermato-Venereologica, 2007, 87, 77-80.	1.3	22
65	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e839-e842.	2.4	22
66	Follicular vitiligo: a new form of vitiligo. Pigment Cell and Melanoma Research, 2012, 25, 527-529.	3.3	20
67	<scp>DLQI</scp> as a major criterion for introduction of systemic agents in patients with mild psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1961-1964.	2.4	19
68	Special Considerations in Children with Vitiligo. Dermatologic Clinics, 2017, 35, 229-233.	1.7	19
69	Cross-cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs). Journal of the American Academy of Dermatology, 2019, 81, 1107-1114.	1.2	19
70	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderateâ€toâ€severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSOâ€BIOâ€REAL). Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2566-2573.	2.4	19
71	Targeting Innate Immunity to Combat Cutaneous Stress: The Vitiligo Perspective. Frontiers in Immunology, 2021, 12, 613056.	4.8	19
72	Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. British Journal of Dermatology, 2016, 174, 667-670.	1.5	18

#	Article	IF	CITATIONS
73	Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: Analysis of a cohort of 239 patients. Journal of the American Academy of Dermatology, 2019, 80, 478-484.	1.2	18
74	Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature. British Journal of Dermatology, 2018, 178, 650-658.	1.5	17
75	Patient Burden is Associated with Alterations in Quality of Life in Adult Patients with Atopic Dermatitis: Results from the ECLA Study. Acta Dermato-Venereologica, 2018, 98, 713-714.	1.3	17
76	Standardizing serial photography for assessing and monitoring vitiligo: A core set of international recommendations for essential clinical and technical specifications. Journal of the American Academy of Dermatology, 2020, 83, 1639-1646.	1.2	17
77	Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study. Journal of Investigative Dermatology, 2021, 141, 1728-1734.	0.7	17
78	Psoriasiform Eruptions During Anti–TNF-α Treatment: Psoriasis or Not?. Archives of Dermatology, 2007, 143, 1593-5; author reply 1595.	1.4	16
79	Clinical repigmentation patterns in paediatric vitiligo. British Journal of Dermatology, 2016, 175, 555-560.	1.5	14
80	Meeting report: Vitiligo Global Issues Consensus Conference Workshop "Outcome measurement instruments―and Vitiligo International Symposium, Rome, Nov 30–Dec 3rd. Pigment Cell and Melanoma Research, 2017, 30, 436-443.	3.3	14
81	TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. British Journal of Dermatology, 2020, 182, 1423-1429.	1.5	14
82	Phenotype and function of circulating memory T cells in human vitiligo*. British Journal of Dermatology, 2020, 183, 899-908.	1.5	14
83	Oral erosive lichen planus and Good's syndrome: just a coincidence or a direct link between the two diseases?. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 506-507.	2.4	13
84	Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors. Acta Dermato-Venereologica, 2017, 97, 731-734.	1.3	13
85	Vitiligo-like lesions in patients receiving anti–programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo. Journal of the American Academy of Dermatology, 2018, 78, e17-e18.	1.2	13
86	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). Dermatology and Therapy, 2020, 10, 1099-1109.	3.0	13
87	Efficacy and safety of <scp>TNF</scp> blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2330-2338.	2.4	13
88	New insights into immune mechanisms of vitiligo. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 44-54.	0.8	13
89	Exogenous Inflammatory Acne due to Combined Application of Cosmetic and Facial Rubbing. Dermatology, 2012, 224, 221-223.	2.1	12
90	Respiratory infections associated with anti-TNFα agents. Médecine Et Maladies Infectieuses, 2017, 47, 375-381.	5.0	12

#	Article	IF	CITATIONS
91	Increased risk of mortality in systemic sclerosisâ€associated digital ulcers: a systematic review and metaâ€analysis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 405-409.	2.4	12
92	Decreased CCN3 in Systemic Sclerosis Endothelial Cells Contributes to Impaired Angiogenesis. Journal of Investigative Dermatology, 2020, 140, 1427-1434.e5.	0.7	12
93	Pancytopenia induced by low-dose methotrexate in a haemodialysis patient treated for bullous pemphigoid. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 1135-1136.	2.4	11
94	Inflammasome Activation Characterizes Lesional Skin of Folliculitis Decalvans. Acta Dermato-Venereologica, 2018, 98, 570-575.	1.3	11
95	Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1578-1583.	2.4	11
96	The humanistic burden of vitiligo: a systematic literature review of qualityâ€ofâ€life outcomes. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1507-1523.	2.4	11
97	Biologics in atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2012, 10, 174-178.	0.8	10
98	Development of a shared decisionâ€making tool in vitiligo: an international study. British Journal of Dermatology, 2021, 185, 787-796.	1.5	10
99	Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: AÂcross-sectional study. JAAD International, 2021, 5, 112-120.	2.2	10
100	An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderateâ€ŧoâ€severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1486-1496.	2.4	10
101	Alternative Procedure to Allow Continuation of Dapsone Therapy despite Serious Adverse Reaction in a Case of Dapsone-Sensitive Erythema Elevatum Diutinum. Dermatology, 2012, 224, 115-119.	2.1	9
102	A Th2 Cytokine Interleukin-31 Signature in a Case of Sporadic Lichen Amyloidosis. Acta Dermato-Venereologica, 2015, 95, 223-224.	1.3	9
103	Factors associated with perceived stress in patients with vitiligo in the ComPaRe e-cohort. Journal of the American Academy of Dermatology, 2022, 86, 696-698.	1.2	9
104	Demographic and clinical characteristics of patients with both psoriasis and vitiligo in a cohort of vitiligo patients: a crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e676-e679.	2.4	9
105	Delayed hypersensitivity skin reaction to hydroxychloroquine: Successful short desensitization. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 307-308.	3.8	8
106	Characteristics of postinflammatory hyper- and hypopigmentation in patients with psoriasis: A survey study. Journal of the American Academy of Dermatology, 2020, 83, 1188-1191.	1.2	8
107	Biologika bei atopischer Dermatitis. JDDG - Journal of the German Society of Dermatology, 2012, 10, 174-179.	0.8	7
108	Successful rapid subcutaneous desensitization to anakinra in a case of delayedâ€ŧype hypersensitivity reaction. British Journal of Dermatology, 2016, 174, 1417-1418.	1.5	7

#	Article	IF	CITATIONS
109	Interleukinâ€1β–Activated Microvascular Endothelial Cells Promote DCâ€5IGN–Positive Alternatively Activated Macrophages as a Mechanism of Skin Fibrosis in Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 1013-1026.	5.6	7
110	Targeting iHSP 70 in vitiligo: a critical step for cure?. Experimental Dermatology, 2013, 22, 570-571.	2.9	6
111	Pigmented lichenoid drug eruption: a new clinical presentation of interface dermatitis induced by anti-TNF alpha drugs. European Journal of Dermatology, 2016, 26, 633-634.	0.6	6
112	Azathioprine in combination with methotrexate: a therapeutic alternative in severe and recalcitrant forms of alopecia areata?. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e494-e495.	2.4	6
113	Assessment of Vitiligo Area Scoring Index (VASI), Facial-VASI and Vitiligo Extent Score using standardized photography of patients with vitiligo. British Journal of Dermatology, 2022, 187, 422-424.	1.5	6
114	Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study. British Journal of Dermatology, 2022, 187, 602-603.	1.5	6
115	A case of primary erythermalgia with encephalopathy. Journal of Neurology, 2009, 256, 1767-1768.	3.6	5
116	Delayed cutaneous hypersensitivity reactions to iodinated contrast media. European Journal of Dermatology, 2017, 27, 190-191.	0.6	5
117	Antiâ€ŧumour necrosis factor αâ€induced lupus erythematosus panniculitis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e318-e319.	2.4	5
118	Response to low-dose intravenous immunoglobulin in a case of recalcitrant Darier disease. JAAD Case Reports, 2020, 6, 189-191.	0.8	5
119	Outâ€ofâ€pocket expenditures in France to manage psoriasis in adult patients: results from an observational, crossâ€sectional, nonâ€comparative, multicentre study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 912-918.	2.4	5
120	Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 435-443.	0.8	5
121	Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme. JAMA Dermatology, 2021, 157, 1472.	4.1	5
122	Alopecia areata: Recent advances and emerging therapies. Annales De Dermatologie Et De Venereologie, 2022, 149, 222-227.	1.0	5
123	Long-Term Use of Systemic Treatments for Moderate-to-Severe Atopic Dermatitis in Adults: A Monocentric Retrospective Study. Acta Dermato-Venereologica, 2014, 96, 802-6.	1.3	4
124	Accelerating bleaching in vitiligo: balancing benefits versus risks. Experimental Dermatology, 2014, 23, 879-880.	2.9	4
125	Pigmented skin patches without scleroderma as a predominant clinical symptom revealing systemic sclerosis. Clinical and Experimental Dermatology, 2016, 41, 379-382.	1.3	4
126	Azathioprineâ€induced rosacea. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e310-e311.	2.4	4

#	Article	IF	CITATIONS
127	A case of lichenoid and pigmented drug eruption to acetazolamide confirmed by a lichenoid patch test. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 283-285.	3.8	4
128	Low cardiovascular risk and poor quality of life associated with tobacco use and skin infections in adult atopic dermatitis: result of a French multicenter study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e451-e453.	2.4	4
129	Imbalance of peripheral follicular helper T lymphocyte subsets in active vitiligo. Pigment Cell and Melanoma Research, 2019, 32, 588-592.	3.3	4
130	Editorial: Immunology of Vitiligo. Frontiers in Immunology, 2021, 12, 711080.	4.8	4
131	The Use of Patch Tests in Determining Hypersensitivity to Etanercept and Infliximab—Reply. Archives of Dermatology, 2008, 144, 1071.	1.4	3
132	Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases. Chemical Immunology and Allergy, 2012, 97, 203-216.	1.7	3
133	Comment: the mystery of melanocyte demise in vitiligo. Experimental Dermatology, 2015, 24, 260-261.	2.9	3
134	Vitiligo therapy: restoring immune privilege?. Experimental Dermatology, 2017, 26, 635-636.	2.9	3
135	Vitiligo, Associated Disorders and Comorbidities (Autoimmune-Inflammatory Disorders,) Tj ETQq1 1 0.784314	rgBT /Overl	ock310 Tf 50 4
136	Psoriasis: frequency and reasons for absenteeism results from a study on 1609 active patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e301-e303.	2.4	3
137	Inflammatory Vitiligo. , 2010, , 99-105.		3
138	Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice. British Journal of Dermatology, 2022, 186, 733-735.	1.5	3
139	Cell delivery using microneedle devices: a new approach to treat depigmenting disorders. British Journal of Dermatology, 2018, 178, 588-589.	1.5	2
140	Elevated total serum IgE in vitiligo might be protective for other autoimmune diseases. British Journal of Dermatology, 2018, 179, 987-988.	1.5	2
141	Clinically Inflammatory Vitiligo and Rare Variants. , 2019, , 81-91.		2
142	Use of mindâ€body practices by patients with psoriasis: results from a study on 2562 patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e305-e307.	2.4	2
143	Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort. British Journal of Dermatology, 2021, 185, 1052-1054.	1.5	2
144	Vitiligo Treatment Impact score (VITs): development and validation of a vitiligo burden of treatment questionnaire using the ComPaRe Vitiligo eâ€cohort. Journal of the European Academy of Dermatology and Venereology, 2021, 36, 279.	2.4	2

#	Article	IF	CITATIONS
145	Correlation of nailfold capillaroscopy findings with history of digital ulcer on same finger: Results of SCLEROCAP study. Microvascular Research, 2022, 142, 104365.	2.5	2
146	Image Gallery: Jacquet papuloâ€erosive dermatitis in an adult. British Journal of Dermatology, 2019, 181, e145.	1.5	1
147	Complete response in a patient with advanced melanoma following antiâ€PDâ€1 therapy is associated with a high frequency of melanomaâ€infiltrating CXCR3 ⁺ resident memory CD8 ⁺ T cells and multiple chemokine pathways. British Journal of Dermatology, 2021, 185, 663-666.	1.5	1
148	EczemaPartner – adapting a questionnaire to assess the impact of atopic dermatitis on partners of patients. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
149	A Score with a VESted InterestÂinÂVitiligo. Journal of Investigative Dermatology, 2016, 136, 902-904.	0.7	Ο
150	Dermatite atopiqueÂ: nouveautés physiopathologiques-cibles moléculairesÂ?. Revue Francaise D'allergologie, 2018, 58, 142-143.	0.2	0
151	Recurrent erysipelas of the face with hyperimmune reaction to group C streptococcus. British Journal of Dermatology, 2018, 179, 524-525.	1.5	Ο
152	Inflammatory skin eruptions induced by anti-tumour necrosis factor-α therapy differ undeniably from psoriasis or eczema. British Journal of Dermatology, 2018, 178, 1007-1008.	1.5	0
153	In vitro models of vitiligo. , 2018, , 129-149.		0
154	An unusual presentation of Sutton's phenomenon presenting as halo cherry angioma. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e464-e465.	2.4	0
155	Vitiligo-Like Lesions in Patients with Metastatic Melanoma Receiving Immunotherapies. , 2019, , 163-167.		0
156	ESDR Academy for Future Leaders in Dermatology: A Springboard for Career Achievement. Journal of Investigative Dermatology, 2020, 140, S187-S188.	0.7	0
157	ls Hyperpigmentation in Systemic Sclerosis a Perivascular Dermal Tattoo?. Journal of Investigative Dermatology, 2020, 140, 2308-2312.e2.	0.7	0
158	The harmful effects of aesthetic care: Dealing with new kinds of exogenous acne. Annales De Dermatologie Et De Venereologie, 2022, , .	1.0	0